Tripterygium glycosides improve abnormal lipid deposition in nephrotic syndrome rat models

Ren Fail. 2023 Dec;45(1):2182617. doi: 10.1080/0886022X.2023.2182617.

Abstract

Objective: The purpose of this study was to determine the effect of tripterygium glycosides (TGs) on regulating abnormal lipid deposition in nephrotic syndrome (NS) rats.

Methods: Sprague-Dawley (SD) rats were injected with 6 mg/kg doxorubicin to construct nephrotic syndrome models (n = 6 per group), and then administered with TGs (10 mg/kg·d-1), prednisone (6.3 mg/kg·d-1), or pure water for 5 weeks. Biomedical indexes, such as urine protein/creatinine ratio (PCR), blood urea nitrogen (BUN), serum creatinine (Scr), serum albumin (SA), triglycerides (TG), total cholesterol (TC)were investigated to evaluate the renal injury of rats. H&E staining experiment was used to assess the pathological alterations. Oil Red O staining was used to assess the level of renal lipid deposition. Malondialdehyde (MDA) and glutathione (GSH) were measured to assess the extent of oxidative damage to the kidney. TUNEL staining was used to assess the status of apoptosis in the kidney. Western blot analysis was performed to examine the levels of relevant intracellular signaling molecules.

Results: After treatment with TGs, those tested biomedical indexes were significantly improved, and the extent of kidney tissue pathological changes and lipid deposition in the kidney was diminished. Treatment with TGs decreased renal oxidative damage and apoptosis. Regarding the molecular mechanism, TGs significantly increased the protein expression levels of Bcl-2 but decreased the levels of CD36, ADFP, Bax, and Cleaved caspase-3.

Conclusion: TGs alleviates renal injury and lipid deposition induced by doxorubicin, suggesting that it may be a new strategy for reducing renal lipotoxicity in NS.

Keywords: Doxorubicin; lipotoxicity; nephrotic syndrome; tripterygium glycosides.

MeSH terms

  • Animals
  • Doxorubicin
  • Glutathione
  • Glycosides
  • Lipids
  • Nephrotic Syndrome*
  • Rats
  • Rats, Sprague-Dawley
  • Tripterygium

Substances

  • Doxorubicin
  • Glutathione
  • Glycosides
  • Lipids

Grants and funding

This work was supported by the Key-Area Research and Development Program of Guangdong Province (No. 2020B1111110007), Science and technology project of Guangzhou (Nos. 202002010004 and 202201020488), Natural Science Foundation of Guangdong Province (Nos. 2017B030314166, 2022A1515010103, and 2022A1515012443), the Specific Research Fund for TCM Science and Technology of Guangdong Provincial Hospital of Chinese Medicine (No. YN2020QN02), Research Fund for Bajian Talents of Guangdong Provincial Hospital of Chinese Medicine (No. BJ2022KY08), Collaborative innovation project of Guangzhou University of Chinese Medicine (Nos. 2021xk69 and 2021xk08), and Special Funds for State Key Laboratory of Dampness Syndrome of Chinese Medicine (Nos. SZ2021ZZ33 and SZ2021ZZ11).